We found that CD166+ pancreatic cancer cells exhibited stronger tumorigenicity than that of CD166- cells, whereas CD166- pancreatic cancer cells exhibited comparatively stronger invasive and migratory activities. Here, ALCAM is linked to familial pancreatic carcinoma.